Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 0.02% Betamethasone Sodium Phosphate
0.02% Betamethasone · 1 trial · 1 indication
The UNC DEMS scale is a participant-specific 10-point scale with a minimum score of 1 (\[1-2\] My symptoms are not a problem. My dry eye does not affect my daily life at all) and a maximum score of 10 (\[9-10\] my symptoms are severe and I need immediate medical care. My dry eye greatly affects my daily life). Participants with a minimum reduction of ≥1 point in UNC DEMS score from baseline were defined as responders, and response rates were summarized by treatment group.
| Arm | Type | Description |
|---|---|---|
| SURF-200 (0.02% betamethasone sodium phosphate in vehicle) | EXPERIMENTAL | One drop twice daily (BID) in the study eye for 14 days. |
| SURF-200 (0.04% betamethasone sodium phosphate in vehicle) | EXPERIMENTAL | One drop BID in the study eye for 14 days. |
| Vehicle | PLACEBO_COMPARATOR | One drop BID in the study eye for 14 days. |
| Name | Type | Description |
|---|---|---|
| 0.02% Betamethasone Sodium Phosphate | DRUG | topical corticosteroid solution |
| 0.04% Betamethasone Sodium Phosphate | DRUG | topical corticosteroid solution |
| Placebo | DRUG | topical vehicle solution |
Inclusion Criteria: 1. Subjects 18 years of age and older who have a diagnosis of dry eye disease and experiencing an episodic flare up. Criteria for the diagnosis must include the following: 1. UNC DEMS score of greater than or equal to 5 but less than or equal to 9 2. Conjunctival hyperemi...
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-319 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Bausch Health Companies Inc. | BHC | 1 | PHASE2 | BL1107 |
0.02% Betamethasone is being studied for the treatment of dry eye disease, specifically for episodic flare-ups of the condition. It is an investigational ophthalmic eye drop formulation developed by Harrow, Inc. that has completed a Phase 2 clinical trial in adults with dry eye disease.
0.02% Betamethasone is being developed by Harrow, Inc., which trades on the Nasdaq under the ticker symbol HROW. Harrow is an eyecare pharmaceutical company focused on ophthalmic products, and this asset is part of its development pipeline for dry eye disease.
0.02% Betamethasone is in Phase 2 development. A single Phase 2 clinical trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication.
0.02% Betamethasone has been evaluated in one completed Phase 2 trial, NCT04734210, titled a study of an eye drop (SURF-200) in subjects with an episodic flare-up of dry eye disease. The trial enrolled 139 participants in the United States and was randomized, double-blind, and placebo-controlled.
Yes, 0.02% Betamethasone is also known as 0.02% Betamethasone Sodium Phosphate. The two names refer to the same ophthalmic drug candidate being developed by Harrow, Inc. for dry eye disease, and it has completed a Phase 2 clinical trial.